TY - JOUR T1 - Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity JF - British Journal of Ophthalmology JO - Br J Ophthalmol SP - 986 LP - 986 DO - 10.1136/bjo.2008.156208 VL - 93 IS - 7 AU - B A Darlow AU - C Gilbert AU - G E Quinn AU - R Azad AU - A L Ells AU - A Fielder AU - A Zin Y1 - 2009/07/01 UR - http://bjo.bmj.com/content/93/7/986.abstract N2 - Only rarely does a new treatment offer a real sea change. An example in the field of neonatology is the use of exogenous surfactant for hyaline membrane disease.1 For the eye, anti-vascular endothelial growth factor (VEGF) drugs may be the therapeutic advance of our time, revolutionising the treatment of vasoproliferative retinopathies including age-related macular degeneration and diabetic retinopathy. In his informative editorial, Sears suggests that anti-VEGF therapy may play a similar role in retinopathy of prematurity.2Retinopathy of prematurity (ROP) is a vasoproliferative disease, and it is therefore not surprising that there is increasing enthusiasm for anti-VEGF drugs.3 4 … ER -